Not to be outdone by other class action firms vying to recruit AMP shareholders for a $2 billion class action, Slater & Gordon announced Friday it would offer investors “the most competitive funding package of all”.
BHP faces possible Australian class action over Brazil mine disaster
Shine joins AMP class action frenzy
DLA Piper’s patent advice to Neurim not privileged, court hears
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company’s founder and her lawyers from DLA Piper.